Seelos’ SLS-005 (Trehalose) Receives EC’s Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis

May 28, 2021 Auto Bot AML, amyotrophic lateral sclerosis, Orphan Drug Designation, regulatory 0

Shots:

  • EMA’s COMP has granted ODD to SLS-005 for the treatment of amyotrophic lateral sclerosis
  • Under ODD, Seelos will get benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity
  • Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the BBB, stabilizes proteins and activates autophagy and has received the US FDA’s ODD in Nov’2020

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

The post Seelos’ SLS-005 (Trehalose) Receives EC’s Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis first appeared on PharmaShots.